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Abstract
Background ACE inhibition results in secondary preven-
tion of coronary artery disease (CAD) through different
mechanisms including improvement of endothelial dys-
function. The Perindopril-Function of the Endothelium in
Coronary artery disease Trial (PERFECT) evaluated whether
long-term administration of perindopril improves endothelial
dysfunction.
Methods PERFECT is a 3-year double blind randomised
placebo controlled trial to determine the effect of perindo-
pril 8 mg once daily on brachial artery endothelial function
in patients with stable CAD without clinical heart failure.
Endothelial function in response to ischaemia was assessed
using ultrasound. Primary endpoint was difference in flow-
mediated vasodilatation (FMD) assessed at 36 months.
Results In 20 centers, 333 patients randomly received
perindopril or matching placebo. Ischemia-induced FMD
was 2.7% (SD 2.6). In the perindopril group FMD went from
2.6% at baseline to 3.3% at 36 months and in the placebo
group from 2.8 to 3.0%. Change in FMD after 36 month
treatment was 0.55% (95% confidence interval −0.36, 1.47;
p=0.23) higher in perindopril than in placebo group. The
rate of change in FMD per 6 months was 0.14% (SE 0.05,
p=0.02) in perindopril and 0.02% (SE 0.05, p=0.74) in
placebo group (0.12% difference in rate of change p=0.07).
Conclusion Perindopril resulted in a modest, albeit not
statistically significant, improvement in FMD.
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Introduction
ACE inhibition has been shown to reduce morbidity and
mortality among a variety of patients, i.e. patients with
congestive heart failure,[1–3], survivors of a myocardial
infarction [4, 5], a-symptomatic patients with left ventric-
ular dysfunction [6, 7], patients with acute myocardial
infarction [8–11], post-myocardial infarction patients [6, 7,
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Rotterdam, The Netherlands12–14] and older high risk patients with documented
coronary heart disease without heart failure and, in some,
no left ventricular dysfunction [15]. Recently, the EUROPA
trial expanded the evidence by showing that ACE inhibition
reduces cardiovascular event risk by 20% among a
relatively low risk population of patients with stable
coronary heart disease without apparent heart failure [16].
In contrast, the PEACE trial study did not show a benefit of
ACE inhibition over placebo [17].
Several mechanisms may explain the beneficial effects
of ACE inhibition on morbidity and mortality [18]. One of
them is the effect of ACE inhibition on shifting the balance
between vasoconstrictive forces (angiotensin II) and vaso-
dilatative forces (bradykinin and nitric oxide) towards
vasodilatation [18]. Also, ACE inhibition may protect
against endothelial apoptosis. These mechanisms lead to
an improvement in endothelial dysfunction. The PERFECT
study, as a sub-study to the EUROPA trial, was designed to
verify the above mentioned pathophysiologic concept [19].
In the PERFECT study, B-mode ultrasonography of the
brachial artery was be used to assess endothelial function in
response to ischaemia (reactive hyperaemia) as measured
by flow mediated vasodilatation (FMD).
The present paper describes the main findings of the
PERFECT study.
Methods
Design
The rationale and design of the PERFECT study has
been detailed elsewhere [19]. In short, the PERFECT
study is a study nested within the EUROPA trial. The
EUROPA trial is a three year double-blind, multi-centre,
placebo-controlled randomised study that aims at studying
the effect of the ACE-inhibitor perindopril on morbidity
and mortality in over 12,000 patients with stable coronary
artery disease without clinical heart failure [16]. The
PERFECT study was designed as a parallel group
randomised placebo controlled trial to determine the effect
of perindopril (8 mg/day) on brachial artery endothelial
f u n c t i o n ,a sa s s e s s e db yF M D .
After a run-in period of 4 weeks with 4 mg/day
perindopril, participants were randomised to perindopril or
placebo. The recruitment for the PERFECT study started in
May 1998. Both the EUROPA trial and the PERFECT
study finished recruitment in June 1999. In the PERFECT
study 333 patients were recruited in 20 European centers (8
in Czech Republic, 1 in Germany, 2 in Greece, 4 in
Netherlands, 4 in Poland and 1 in Sweden). Endothelial
function, measured as FMD was assessed at the baseline
visit, just before the run-in period. Follow-up B mode
ultrasound for FMD assessment were performed at 6, 12,
24 and 36 months after randomisation.
In addition, an endothelial independent vasodilatation
test (NTG) using nitroglycerine sublingually, was per-
formed at baseline and at 36 months after randomisation.
The NTG measurements were performed without withhold-
ing of used medications.
Study population
The population enrolled in the PERFECTstudy is similar to
that enrolled in the EUROPA trial [16]. In short, the main
inclusion criteria are 18 years of age or above; documented
coronary artery disease, not scheduled for re-vascularisation
and informed consent obtained. Documented coronary heart
disease includes a history of previous myocardial infarction
(confirmed by ECG demonstrating Q waves in two contig-
uous leads and/or changes in cardiac enzymes more than or
equal to twice the normal values) of at least 3 months prior to
the selection visit, or, a history of PTCA or CABG of at least
6 months prior the selection visit, or, abnormal findings at
coronary angiography (angiographical evidence of ≥70%
narrowing of ≥1 major coronary artery according to visual
analysis). Also, men with a history of chest pain documented
by either a positive exercise test or by the development of
regional wall motion abnormalities during stress echocardi-
ography or nuclear scintigraphy or perfusion defects during
scintigraphy perfusion imaging could be included.
The main exclusion criteria were clinical signs of heart
failure requiring treatment; systolic blood pressure
<100mmHg;uncontrolled treated hypertension withsystolic
blood pressure >180 mmHg and/or a diastolic blood pressure
>100 mmHg; use of ACE inhibitors or angiotensin II
receptor inhibitors within 1 month prior to the first selection
visit; renal failure with serum creatinine >150 μmol/l; serum
potassium >5.0 mmol/l; liver disease with liver enzymes >3
times upper normal values; a history of stroke or cerebral
transient ischaemic attacks within the preceding 3 months
and known intolerance to ACE inhibitors.
All patients who participated in the main EUROPA study
and had been enrolled in study centres that participated in
the PERFECTstudy, were additionally invited to participate
in the PERFECT study. All those patients that were willing
and gave informed consent were considered as PERFECT
participants. Since refusal rates for PERFECT were as-
sumed to be independent of the treatment assignment, it
was expected that the PERFECT participants would
resembles closely the EUROPA participants.
PERFECT study measurements
The study outcomes were (1) absolute change in FMD
percentage of the brachial artery between the 36 month
270 Cardiovasc Drugs Ther (2007) 21:269–279measurement and the baseline measurement, (2) absolute
change in FMD percentage of the brachial artery between
the 6 month measurement and the baseline measurement,
(3) Rate of change in FMD in 36 months.
Assessment of brachial artery flow mediated vasodilatation
(FMD)
Preceding the start of the PERFECTstudy, a detailed training
programme was implemented to ensure standardisation of the
FMD measurements across all centers. Based on the
performance during and after the training programme all
sonographers entered the certification procedure.
Ultrasound examinations were performed using a Du-
plex scanner with a >7 MHz or 7–10 MHz linear array
transducer, with on line ECG recording. The examinations
were recorded on (S-)VHS videocassette and sent to a core
laboratory for off line reading. The details of the measure-
ment have been detailed elsewhere [19]. In short, patients
were studied in supine position. Three ECG leads were
attached. The arm was placed in a specifically developed
splint to reduce arm movements during the procedure as
much as possible and to allow for fixation of the ultrasound
transducer. The blood pressure cuff was placed just below
the elbow, and below the ultrasound transducer. After a
10 min rest, the brachial artery at the elbow was visualised
using a ultrasound machine with a >7 MHz or 5–10 MHz
linear array transducer. When a satisfactory longitudinal
optimal image of the brachial artery was obtained, the
position of the transducer was fixed in the holder. Three B-
mode images showing the lumen diameter were frozen on
the R-wave of the ECG to provide information for off-line
measurement of the ‘baseline’ lumen diameter for the
ischemia test. Then the blood pressure cuff was inflated to
suprasystolic levels (50 mmHg above) for a four-minute
period. During that time the sonographer checked whether
the optimal image was steady. After deflation of the blood
pressure cuff, ultrasound examination continued for 5 min.
Every 15 s a B-mode image was frozen on the R-wave of
the ECG (end-diastole) for off-line lumen diameter meas-
urements [20, 21].
At baseline and at month 36 the effect of nitroglycerine
was evaluated after the ischemia test using a similar
procedure as described above. When a satisfactory longitu-
dinal optimal image of the brachial artery was obtained,
three B-mode images showing the lumen diameter were
frozen on the R-wave of the ECG to provide information
for off-line measurement of the ‘baseline’ lumen diameter
for the nitroglycerine test. Then 400 μg of nitroglycerine
were sublingually administered. The ultrasound examina-
tion continued for another 5 min. Every 15 s a B-mode
image was frozen on the R-wave of the ECG (end-diastole)
for off-line lumen diameter measurements.
The off line reading of the PERFECT Study ultrasound
examinations was done using Brachial Tools®, version
3.2.6 (Medical Imaging Applications, Iowa, USA). In short,
first the frozen images on videotape are digitised and put
into a time sequence. Then the reader manually identifies
the part of the brachial artery in which the boundaries are
good and stable visualised in all these images. Next, the
Brachial Tools® software detects the boundaries through all
these images and provides numerical data on lumen
diameters of all the images. The diameter at baseline was
based on the average of the three frozen images. FMD was
estimated as [maximal lumen diameter after ischemia−
diameter at baseline]/diameter at baseline. The nitroglycer-
ine response (flow independent vasodilatation) was estimated
as [maximal lumen diameter after nitroglycerine−diameter at
baseline]/diameter at baseline.
Sample size considerations
At the start of the preparations of the PERFECT study in
1998, an estimate of what was considered a clinically
relevant difference in FMD from baseline varied between
1.8 and 6.7% in the published literature. In a study among
subjects who underwent coronary angiography, the positive
predictive value of FMD less than 3% in predicting
coronary endothelial dysfunction was 95% [22]. It had
been argued that in clinical trials the number of subjects
needed should be such that at least a 2% difference in FMD
is detectable [23]. In an earlier study performed by our
group, among 32 healthy volunteers the mean FMD was
7.7% (SD 5.0) [24]. Since the present study is a multi-
centre which generally increases the variability in the FMD
measurements compared to single-centre studies, the
sample size calculation is to be considered conservative.
With a 90% power, a two-sided alpha of 5%, an absolute
difference in FMD of 2.0% can be assessed with a sample
size of 131 subjects in each arm of the trial. With an
anticipated 10% drop-out rate in the EUROPA trial, a total
of 288 subjects needed to be randomised.
Data analysis
General characteristics of the study population were given
according to the intention to treat principle (ITT). The ITT
population comprised patients who had a 6 month FMD
measurement for the analyses on 6 month change in FMD.
For 36 month change the ITT population comprised
patients with 36 month FMD data. For the rate of change
analyses, the ITT population comprised of all those
patients who had at least one 6 month baseline FMD
value. Those patients who had no follow-up FMD
measurements or those who had inadequate measurements
were excluded for the statistical analyses. Absence to
Cardiovasc Drugs Ther (2007) 21:269–279 271 271compliance of treatment was not a reasons to exclude
patients from the analyses.
For each patient the difference in FMD at 6 month and
baseline was calculated (FMD value at 6 months−FMD
value at baseline). A similar approach was used for
36 month difference in FMD. Next, linear regression
analyses were applied to study whether the 6 month or
36 month differences in FMD differed between treatment
groups using difference in FMD as dependent variable and
treatment assignment as independent variable. No adjust-
ments were additionally made since the treatment assign-
ment was achieved using a randomisation procedure. These
analyses were carried out using SPSS statistical package
(version 12.0). This analytic approach had a priori been
decided upon although we recognise that for the 36 month
effects the reduction in sample size due to the absence of
36 month measurements could be considerable.
To evaluate differences in rate of change of FMD
between treatment groups a random effects model was
applied using SAS statistical software (version 8.1). Apart
from the assumption that the change in FMD is linear over
time, we made no assumptions for the intercept (random) of
the model and for correlation structure (unstructured)
between repeated FMD measurements. The primary model
Table 1 General characteristics of the PERFECT study population by assigned treatment
Characteristic Perindopril (n=167) Placebo (n=166)
Age (years) 60.8 8.9 60.0 9.6
Female gender (%) 21 12
Medical history (%)
Previous myocardial infraction 59.9 63.6
Previous PTCA 40.1 42.2
Previous CABG 36.5 34.9
Abnormal CAG 76.0 72.9
History of chest pain and positive exercise test 9.6 15.7
Previous TIA/stroke 4.2 3.0
Peripheral arterial disease 10.2 9.0
Diabetes mellitus 16.8 15.7
Current drug use (%)
Platelet Inhibitors 94.0 95.2
Lipid lowering 62.9 63.9
Beta blockers 78.4 73.5
Calcium antagonists 32.9 27.1
Nitrates 40.1 36.7
Diuretics 12.0 13.3
SBP (mmHg) 137 16.0 135 14.8
DBP (mmHg) 80.9 8.0 80.2 8.0
History of hypertension (%) 53.9 41.6
Heart rate (bpm) 66.6 9.9 65.7 8.0
Height (cm) 171.9 8.0 173.4 7.5
Weight (kg) 82.3 12.3 82.9 12.4
Current smoking (%) 11.4 12.0
Total cholesterol (mmol/l) 5.1 0.84 5.2 0.93
HDL (mmol/l) 1.26 0.32 1.28 0.36
LDL (mmol/l) 3.02 0.81 3.03 0.78
Hypercholesterolaemia (%) 69.5 66.9
Brachial artery measurements
FMD (%) 2.62 2.64 2.87 2.58
Baseline diameter FMD (mm) 5.02 0.80 5.05 0.92
Maximal diameter FMD (mm) 5.147 0.79 5.19 0.94
NTG response (%) 9.47 5.9 9.05 5.8
Baseline diameter NTG (mm) 5.05 0.79 5.08 0.93
Maximum diameter NTG (mm) 5.52 0.80 5.51 0.90
Values are means with standard deviations or percentages. Significance testing, excluding whether a difference is due to chance is useless, since all
potential differences were due to chance because of the randomisation process
NTG Nitroglycerin, FMD flow mediated dilatation, LDL low density lipoprotein, HDL high density lipoprotein, SBP systolic pressure, DBP
diastolic pressure, TIA transient ischemic attack, CAG coronary angiogram, CABG coronary artery bypass grafting, PTCA percutaneous coronary
angioplasty
272 Cardiovasc Drugs Ther (2007) 21:269–279FMD percentage as outcome, and had as independent
variables assigned treatment group, visit time from base-
line, and the interaction term time×group assignment. Rate
of change was estimated per 6 month intervals. The
advantage of using a random effects model above the
earlier mentioned analytic approaches is that all FMD
measurements that have been performed during the study
will be used in the analyses and thereby increasing the
power.
Although this is a randomised controlled trial and
therefore in principle adjustment for other variables is not
needed, we did perform analyses where adjustments were
made for study center and for those factors that were
imbalanced at baseline (gender, chest pain, hypertension).
Reproducibility of the FMD measurement was assessed
using the information of the FMD measurement at baseline
and at the 6 month visit in the placebo group. Overall
reproducibility, i.e., reflecting the combined variability due
to between and within sonographer, and between and
within reader and between visit aspects, was evaluated
using Intraclass correlation coefficient.
Results
The general characteristics of the 333 randomised partic-
ipants are given in Table 1. Overall the characteristics,
including the brachial artery measurements were well
balanced between treatment groups except for some factors.
The perindopril group comprised more men and more
patients with a history of hypertension. In contrast, chest
pain was less common. Out of these 333 subjects
information on FMD was considered too poor in 20
subjects to be evaluated in the study. These subjects (9 in
the perindopril group) were therefore not used in the further
analyses with FMD. Figure 1 depicts the distribution of the
FMD measurements at baseline (top) and the nitroglycerine
response measurements (bottom) among the participants.
Follow-up measurement of FMD at 6 month visit, 12 month
visit, 24 months and 36 month visits were done in 325, 324,
319, and 301 patients, respectively. Of those, the FMD
scans indicated of sufficient quality were 310, 292, 293 and
268, respectively. For NTG measurements at baseline and
end of study these figures were 330, 286, 304 and 258,
respectively. Data on the reproducibility of the FMD
measurement was based on 145 repeat scans within a
6 month time frame, and combined the effects of variance
due to the assessment (technical and biological) and due to
the offline measurement. The latter has been documented
earlier [19], and showed an Intraclass correlation coefficient
of 0.65 for the ischemia test. The overall reproducibility
was moderate with an Intraclass correlation of 0.12 (p=
0.25). Restriction to centers with higher reproducibility
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Fig. 1 Distribution of FMD values and NTG values at baseline in the
PERFECT study participants
Cardiovasc Drugs Ther (2007) 21:269–279 273 273findings did not materially affect the main findings,
therefore results pertaining to all participants are presented.
In Fig. 2 the FMD response over time is presented. An
improvement is seen in the perindopril group, starting after
12 months, whereas in the placebo group the trend is
towards no change over time.
The mean change in FMD between baseline and
36 months was 0.91% (SD 3.77) in the perindopril group
and 0.35% (SD 3.63) in the placebo group. The change in
FMD of the brachial artery between the 36 month mea-
surement and the baseline measurement was 0.55 % (95%
confidence interval −0.42 1.47; p value 0.23) higher in the
perindopril group compared to placebo. This statistically
non-significant difference constitutes a relative improve-
ment in FMD of 20% (=0.55/2.74). This analysis was based
on measurements available at both baseline and 36 month
of 256 participants. Adjustment for center or for imbalances
at baseline did not materially affect the magnitude, direction
or significance of the intention-to-treat estimate.
The change in flow-mediated vasodilatation of the
brachial artery between the 6 month measurement and the
baseline measurement between treatment groups was
−0.12% (95% CI −0.87, 0.85; p value 0.97). This analysis
was based on measurements available at both baseline and
6 months of 294 participants. Adjustment for center or for
imbalances at baseline did not materially affect the
magnitude, direction or significance of the intention-to-
treat estimate.
The rate of change in endothelial function per 6 months
as estimated by a random effect model using data of all
participants was 0.14% (SE 0.05, p=0.02) in the perindo-
pril group and 0.02% (SE 0.05, p=0.74) in the placebo
group (Fig. 3) The difference in rate of change in FMD
between the treatment arms was 0.12% (p=0.07). Adjust-
ment for center or for imbalances at baseline did not
materially affect the magnitude, direction or significance of
the intention-to-treat estimate.
No difference in nitroglycerine response results at
36 months was found between perindopril and placebo.
Mean values (SD) were 8.2% (5.4) and 8.8% (5.4),
respectively.
Discussion
The PERFECT study was designed to evaluate whether
long-term administration of perindopril improves endothe-
lial dysfunction in patients with stable CAD and without
clinical heart failure. Our findings, analysed in two ways,
indicate that long-term use of perindopril is compatible with
an improvement in FMD, although these findings were not
statistically significant. The rate of change in endothelial
function per 6 months showed a significant improvement
over time in the perindopril group, where the comparison
with placebo showed that these improvements bordered on
statistical significance (p of 0.07).
The mechanisms underlying the beneficial effects
of ACE inhibition are complex, and include inhibition of
angiotensin II production with, subsequently, a reduction of
its negative effects on the vascular system. Through
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Fig. 2 Mean FMD (standard
errors) by visit and assigned
treatment group (perindopril
dotted; placebo solid)
274 Cardiovasc Drugs Ther (2007) 21:269–279coupling to the angiotensin II type 1 receptor, angiotensin II
leads to vasoconstriction, vascular inflammation with an
increase in pro-inflammatory genes, adhesion molecules
and macrophage recruitment, an increased uptake and
oxidation of LDL by endothelial cells and oxyradical
production leading to endothelial dysfunction. Furthermore,
it stimulates sympathetic activation and aldosterone release,
adding to vasoconstriction and endothelial dysfunction.
ACE inhibitors may positively affect endothelial dysfunc-
tion by decreasing angiotensin II production alone. How-
ever, equally or possibly more important is their effect on
bradykinin. Through coupling to the bradykinin B2
receptor bradykinin results in NO and endothelial-derived
hyperpolarizing factor. In addition it promotes prostacyclin
release. As a consequence, bradykinin is not only a strong
vasodilator, it also inhibits, through NO production,
vascular smooth muscle cell growth and migration,
improves endothelial function, inhibits the expression of
cell adhesion molecules, prevents platelet adhesion, and
restores the fibrinolytic balance by tPA production. As
such, bradykinin effectively counteracts the deleterious
effects of angiotensin II. The improvement of endothelial
function with ACE inhibition is bradykinin-dependent [25].
Of importance, not all ACE inhibitors increase bradykinin
production to a similar extent. This depends, amongst other
factors, on tissue affinity of the ACE inhibitor. Perindopril
is one of the few ACE inhibitors with profound tissue
affinity [26]. It increases bradykinin significantly more than
enalapril despite similar effects on circulating angiotensin II
[27]. Also, perindopril increases bradykinin levels at lower
doses than needed to reduce angiotensin II levels [28].
Indirectly, the pivotal role of bradykinin on endothelial
function is suggested by the observation that perindopril,
but not an angiotensin receptor antagonist telmisartan,
improves endothelium-dependent vasodilatation, after
long-term treatment despite similar anti-hypertensive
effects [29]. The PERTINENT study, another sub-study of
EUROPA, provides further evidence in support for the
improvement in endothelial function observed in the
PERFECT study [50]. PERTINENT studied the effect of
8 mg perindopril versus placebo after one year treatment on
plasma markers of atherosclerosis, neurohormonal activa-
tion and apoptosis. A significant reduction in angiotensin II
and cytokine levels was found together with a reduction in
apoptosis. Of importance, bradykinin increased significant-
l ya c c o m p a n i e db ya ni n c r e a s ei ne c N Os y n t h a s ei n
perindopril but not in placebo treated patients. These data
from a similar patient population as in PERFECT provide
evidence that pivotal mechanisms in endothelial function
are improved by perindopril treatment and could lead to an
improvement in endothelial function, as indicated in
PERFECT.
There have been several studies performed on the effect
of ACE inhibition and endothelial function as measured by
FMD of the brachial artery (Table 2)[ 30–42]. Most studies
were single centre studies, had a limited number of subjects
enrolled (varying from 9 to 46), and were of short duration
(from postprandial effect to 6 months). The designs applied
were mostly cross-over trials. Overall, the effects varied
from beneficial effects on FMD response to no effect at all
without consistency in patient groups. That severely limits
direct comparison with our results. In PERFECT the first
FMD measurement after randomisation was at 6 months.
No difference in FMD was found at 6 months between
treatment groups. Our study is unique in that we studied
long term effects of intervention on FMD. A recent review
of studies on the long term effect of ACE inhibition on
endothelial function, as assessed by a variety of measure-
ments (vascular response and/or plasma markers) conclud-
ed that for CAD patient results are consistently showing an
improvement in endothelial function [43]. This is substan-
tiated by the results from trials showing that coronary
p < 0.07 
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ment with ACE inhibitors [44].
Some aspects of the study need some consideration to
appreciate the findings. Firstly, the initial sample size
estimation was based on assumptions that came from
cross-sectional studies, since longitudinal data were not
available. When we perform a posterior power calculation
based on the availability of 240 subjects using actually
observed data on the difference between baseline and
36 months in FMD in the control arm (0.35% with a SD
3.63), we had a 80% power to detect a difference in change
from baseline between the perindopril group and the
placebo group of 1.3%, assuming a two sided alpha of
0.05. Our power to detect a 2% difference, as was originally
proposed, was even higher. However, our power to detect
the currently observed difference of 0.55% was only 20%,
suggesting that we can not really exclude the fact that
perindopril may have an effect on endothelial function.
Secondly, it has been documented that the value of FMD
measurement may be affected considerably by life style
habits, such as recent physical activity, smoking, and food
intake, technical aspects of the measurement, such as cuff
Table 2 Studies performed on the effect of ACE inhibition and endothelial function as measured by FMD of the brachial artery
Author Publication
year
Study design Type of patient Follow-up Intervention Control arm Findings
Yavuz
[31]
2003 RCT Essential
hypertensives
6 months Enalapril (n=12) Losartan
(n=9)
FMD improved
under both
treatments
Tezcan
[32]
2003 Case control Essential
hypertensives
versus healthy
controls
6 months Enalapril (n=9) FMD improved
under enalapril
Ghiadoni
[33]
2003 RCT
(before/
after)
Essential
hypertension
6 months Nifedipine (n=28)
amlodipine (n=28) atenolol
(n=29) nebivolol (n=28)
telmisartan (n=29)
perindopril (n=28)
FMD improved
under perindopril
only
Ellis [34] 2002 RCT Stable heart
failure
1 month Ace inhibition plus
candersatan (n=14)
Ace
inhibition
plus
placebo
(n=14)
No difference in
FMD
Bae [35] 2001 RCT Angiographically
CAD
Postprandial Lisinopril High fat
/low fat/
fenofibrate
No effect of FMD
Cheetham
[36]
2001 Cross over
RCT
Type II diabetes 4 weeks Losartan (n=12) Placebo Improvement of
FMD
Schalwijk
[37]
2000 Case control Type II diabetes/
healthy controls
5 weeks Quinapril Placebo No difference in
FMD
Anderson
[38]
2000 Cross over
RCT
Stable CHD
patients
8 weeks Quinapril (n=20) enalapril
(n=20) losartan (n=20)
amlopidine (n=20)
FMD improved only
under quinapril
McFarlane
[39]
1999 Cross over
RCT
Type I diabetes 12 weeks Perindopril (n=20) Triamterene No effect on FMD
of perindopril
Koh [40] 1999 Before/
after
comparison
CHD 8 weeks Quinapril (n=9) Improvement in
FMD
Wilmink
[41]
1999 Cross over
RCT
Healthy
volunteers
2 weeks Quinapril (n=30) losartan
(n=30)
No improvement in
basal FMD ,
improvement in
postprandial FMD
reduction
Mullen
[42]
1998 RCT Insulin diabetes 24 weeks Enalapril (n=46) Placebo
(n=45)
No effect on FMD
RCT Randomised controlled trial, CHD coronary heart disease, FMD flow mediated vasodilatation
276 Cardiovasc Drugs Ther (2007) 21:269–279location, and concomitant drug treatment, such as statins
[45–48]. Furthermore, the reproducibility of the FMD
measurement in situations where lifestyle factors were
controlled optimally, may be moderate with coefficients of
variation between 25–50%, indicating that within person
variability may be considerable [49]. This in general leads
to attenuation of the magnitude of the relations under study.
Although in PERFECT a uniform training and FMD
methodology was used, the study was a multicenter trial,
which compared to single center studies generally increases
variability as shown by our reproducibility findings. This
was one of the reasons we applied a random effect model to
increase the power of the study to detect meaningful
differences between treatment arms.
The baseline FMD value in our population was low,
similar to that found in other studies in CAD patients [48],
and may indicate the presence of endothelial dysfunction in
this group. The effect of ACE inhibition on FMD over time
was modest, although significant. This may be partially
attributed to the fact that most of our patients were using
multiple drugs that improve endothelial function as well,
for example statins [49]. This may have reduced our ability
to demonstrate the full benefit of ACE inhibition per se.
In conclusion, appreciating the variability in the FMD
measurement and the widespread use of other drugs that
may affect FMD, our findings are compatible with the
notion that the beneficial effects of perindopril on cardio-
vascular morbidity and mortality in the EUROPA study
may be at least partly explained by an improvement in
endothelial function.
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